Strong Revenue Growth
ATEC reported a total revenue of $197 million in Q3 2025, representing a 30% increase year-over-year. Surgical revenue grew by 31% compared to the prior year period.
Increased Surgeon Adoption
New surgeon users increased by 26% in Q3 2025, indicating strong adoption of ATEC's procedures. Same-store sales grew by 30% year-over-year.
Positive Free Cash Flow
ATEC reported positive free cash flow of $5 million for the quarter and $14 million in cash from operating activities.
Raising Full Year Guidance
Due to strong performance, ATEC raised its full year revenue guidance by $18 million to $760 million.
Record Adjusted EBITDA
The company achieved a record adjusted EBITDA of $26 million in Q3 2025, with an 840 basis points improvement year-over-year.
Expansion of Product Offerings
ATEC is expanding its product offerings with multiple new products in the pipeline, including mechanized arms and new solutions for lateral and cervical spine surgeries.
Strong Balance Sheet
ATEC ended the third quarter with $156 million in cash and $60 million of available borrowing on the revolving credit line, totaling $216 million in cash and available cash.